Paolo Paoletti, formerly head of the oncology business of GlaxoSmithKline Plc, has been appointed executive chairman of Kesios Therapeutics Ltd, an oncology drug discovery company. Kesios is a portfolio company of Imperial Innovations Plc of the UK and was created to develop findings by Guido Franzoso and colleagues at Imperial College London relating to a potential drug target for multiple myeloma.
During his tenure at GSK, Dr Paoletti oversaw the approval of seven new medicines to treat different types of cancer. Earlier this year, GSK sold its portfolio of marketed cancer drugs to Novartis.
Dr Paoletti is also a non-executive director of PsiOxus Therapeutics Ltd, which is developing cancer vaccines. PsiOxus is also in the Imperial portfolio.
Imperial Innovations announced the appointment on 29 May 2015.
Copyright 2015 Evernow Publishing Ltd